Literature DB >> 29090462

Ethnic variations in the epidemiology of bullous pemphigoid in Israel.

Khalaf Kridin1, Reuven Bergman1,2.   

Abstract

BACKGROUND: No ethnic or geographic predisposition to bullous pemphigoid (BP) was reported so far.
OBJECTIVE: To evaluate trends in the incidence of BP in northern Israel, shedding light on differences between two distinct ethnic populations who inhabit the same region, namely Jews and Arabs.
METHODS: Bullous pemphigoid incidence was retrospectively estimated from January 2000-December 2015 in two Israeli regions with a total population of 1.56 million inhabitants.
RESULTS: A total of 287 new-onset BP patients (mean age: 77.6 ± 12.1) were identified. The incidence rate was 11.4 per million inhabitants per year (95% CI, 10.2-12.9). The crude incidence rate in Jews was 4.8-fold higher than that in Arabs (16.4 vs. 3.4 cases per million per year, respectively [P < 0.0001]). After adjusting for age, the discrepancy between the two populations diminished (11.7 vs. 8.9 cases per million per year, respectively) but remained statistically significant (P = 0.032). The incidence increased consistently from 7.6 cases per million per year in the calendar period 2000-2005 to 12.6 and 14.3 cases in 2006-2010 and 2011-2015, respectively (P < 0.0001). Bullous pemphigoid patients of Arab ancestry presented with the disease significantly earlier than Jews (69.5 ± 15.3 vs. 78.7 ± 11.1 years, respectively, P = 0.002).
CONCLUSIONS: The incidence of BP in northern Israel has increased in the last 16 years and is significantly higher among Jews compared to Arabs. The age of presentation is remarkably different between patients belonging to the two populations.
© 2017 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2017        PMID: 29090462     DOI: 10.1111/ijd.13813

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  9 in total

1.  Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.

Authors:  Seon Gu Lee; Hee Jung Lee; Moon Soo Yoon; Dong Hyun Kim
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

2.  Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

3.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

Review 4.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

5.  Relationship between bullous pemphigoid and metabolic syndrome: a 12-year case-control study conducted in China.

Authors:  Bingjie Zhang; Xinyi Chen; Yangchun Liu; Fangyuan Chen; Nan Yang; Li Li
Journal:  Ther Adv Chronic Dis       Date:  2022-10-15       Impact factor: 4.970

Review 6.  The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations.

Authors:  Khalaf Kridin; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2018-08-20

7.  Anti-p200 Pemphigoid: A Systematic Review.

Authors:  Khalaf Kridin; A Razzaque Ahmed
Journal:  Front Immunol       Date:  2019-10-22       Impact factor: 7.561

Review 8.  Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.

Authors:  Karim Chouchane; Giovanni Di Zenzo; Dario Pitocco; Laura Calabrese; Clara De Simone
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

9.  IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker.

Authors:  Yiman Wang; Xuming Mao; Yangchun Liu; Yuyan Yang; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.